Skip to main content
. 2015 Sep 1;2015:204826. doi: 10.1155/2015/204826

Table 2.

Incidence of patients that developed cardiac complications. Data are expressed as the number of patients in each group.

Cardiovascular complications β-blockers (N = 205) No β-blockers (N = 315) p value
Acute coronary syndrome (%) 1 (0.5%) 0 (0 %) n.s.
Atrial fibrillation (%) 29 (14.1%) 49 (15.6%) n.s.
CHF (%) 1 (0.5%) 0 (0%) n.s.
Other 3 (1.5%) 3 (0.9%) n.s.
Composite cardiac endpoints 34 (16.6%) 52 (16.5%) n.s.